Biological Determinants and Risk Factors for Tardive Dyskinesia in Schizophrenia

References

• Agren H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. II: suicide. Psychiatry Research 1980; 3: 225–236
   PubMed Web of Science ®Google Scholar
• Aldegunde M., Miquez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Alpert M., Diamond F., Weisenfreund J., Taleporos E., Friedhoff A. J. The neuroleptic hypothesis: study of the covariation of the extrapyramidal and therapeutic drug effect. British Journal of Psychiatry 1978; 133: 169–175
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders (3rd ed.). APA., Washington, DC 1980
   Google Scholar
• Ammons R. B., Ammons C. H. The Quick Test (QT). Provisional Manual. Psychological Reports 1962; 11: 111–161, Monogr. Suppl. I-VII
   Web of Science ®Google Scholar
• Asberg M., Traskman L., Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor. Archives of General Psychiatry 1976; 33: 1193–1197
   PubMed Web of Science ®Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Horiwn K. The recognition and management of drug-induced movement disorders (reversible type). Presented at the 137th annual meeting of the american psychiatric association, Los Angeles, CA, 1984
   Google Scholar
• Casey D. E., Denney D. Pharmacological characterisation of tardive dyskinesia. Psychopharmacology 1977; 54: 1–9
   PubMed Web of Science ®Google Scholar
• Casey D. E., Keepers G. A. Neuroleptic-side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacology: current trends (Psychopharmacology Supplementum 2), D. E. Casey, A. V. Christensen. Springer-Verlag, Berlin 1988
   Google Scholar
• Chase L. S., Silverman S. Prognostic criteria in schizophrenia: A critical survey of the literature. American Journal of Psychiatry 1941; 98: 360–368
   Google Scholar
• Coccaro E. F., Sever L. J., Klar H. M. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 1989; 46: 587–590
   PubMed Web of Science ®Google Scholar
• Cole J. O., Gardos G., Schniebolk S. Differences in incidence of tardive dyskinesia with different neuroleptics. Tardive dyskinesia and neuroleptics: from dogma to reason, D. E. Casey. American Psychiatric Press., Washington, DC 1986
   Google Scholar
• Datta P. C., King M. G. Melatonin: effects on brain and behavior. Neuroscience & Biobehavioral Reviews 1980; 4: 451–458
   PubMed Web of Science ®Google Scholar
• Davis J. M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33: 858–861
   PubMed Web of Science ®Google Scholar
• Fanget F., Claustrat B., Dalery J., Brun J., Terra J. L., Marie-Cardine M., Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25: 499–501
   PubMed Web of Science ®Google Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Fleischhauer J., Kocher R., Hobi V., Gilsdorf U. Prevalence of tardive dyskinesia in a clinic population. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer-Verlag., Berlin 1985; 163–172
   Google Scholar
• Gardos G., Cole J. O., Salomon M., Schniebolk S. Clinical forms of severe tardive dyskinesia. American Journal of Psychiatry 1987; 144: 895–902
   PubMed Web of Science ®Google Scholar
• Gureje O. Y. E. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
   PubMed Web of Science ®Google Scholar
• Gureje O. Y. E. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychological Medicine 1989; 19: 121–128
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology (rev. ed.). U.S. Department of Health, Education and Welfare., Washington, DC 1976
   Google Scholar
• Jaffe R. B. The menopause and perimenopausal period. Reproductive endocrinology: physiology, pathophysiology and clinical management, S. S. C. Yen, R. B. Jaffe. W. B. Saunders., Philadelphia 1986; 406–423
   Google Scholar
• Jaszmann L. J. B. Epidemiology of the climacteric syndrome. The management of the menopause and postmenopausal years, S. Campbell. University Park Press, Baltimore 1976; 12
   Google Scholar
• Kane J. M., Smith J. M. Tardive dyskinesia: Prevalence and risk factors. 1959–1979. Archives of General Psychiatry 1982; 39: 473–481
   PubMed Web of Science ®Google Scholar
• Kane, Woerner J. M. M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer-Verlag, Berlin 1985; 72–78
   Google Scholar
• Kane I. M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988; 8: 52S–56S, suppl
   PubMed Web of Science ®Google Scholar
• Kaplan H. I., Sadock B. J. Modern Synopsis of Comprehensive Textbook of Psychiatry/IV. 4th Edition. Williams & Wilkins, Baltimore 1985; 194–225
   Google Scholar
• Kaufmann C. A., Jeste D. V., Shelton R. C., Linnoila M., Kafka M. S., Wyatt R. J. Noradrenergic and neuroradiological abnormalities in tardive dyskinesia. Biological Psychiatry 1986; 21: 799–812
   PubMedGoogle Scholar
• Kay S. R., Fiszbein A., Opler L. A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Kay S. R., Opler L. A., Lindenmayer J. P. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Research 1988; 23: 99–110
   PubMed Web of Science ®Google Scholar
• Kay S. R., Opler L. A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS). Multi-Health Systems Inc, Toronto, in press
   Google Scholar
• Kidger T., Barnes T. R. E., Trauer T., Taylor P. J. Sub-syndromes of tardive dyskinesia. Psychological Medicine 1980; 10: 513–520
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Korsgaard S., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology 1985; 118: 245–252
   PubMed Web of Science ®Google Scholar
• Kozell L., Sandyk R., Wagner G. C., Fisher H. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat. Life Sciences 1987; 41: 1739–1744
   PubMed Web of Science ®Google Scholar
• Lindstrom L. H. The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 1988; 77: 524–529
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Department of Health. Education, and Welfare, Washington, DC 1974
   Google Scholar
• Ninan P. T., Van Kammen D. P., Scheinin M., Linnoila M., Bunney W. E., Goodwin F. K. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry 1984; 141: 566–569
   PubMed Web of Science ®Google Scholar
• Oreland L., Wiberg A., Asberg M. Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Research 1981; 4: 21–29
   PubMed Web of Science ®Google Scholar
• Overall J. E., Gorham D. R. Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 799–812
   Web of Science ®Google Scholar
• Owens D. G. C., Johnstone E. C., Crow T. J., Frith C. D., Jagoe J. K., Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine 1985; 15: 27–41
   PubMed Web of Science ®Google Scholar
• Payne R. W. Cognitive abnormalities. Handbook of abnormal psychology, H. J. Eyscnck. Pitman Medical Press., London 1973
   Google Scholar
• Phillips I. Premorbid Adjustment Scale. Journal of Nervous and Mental Disease 1953; 117: 515–525
   PubMed Web of Science ®Google Scholar
• Reiter R. J., Richardson R. A., Johnson L. Y., Ferguson B. N., Dinh D. T. Pineal melatonin rhythm: reduction in aging syrian hamsters. Science 1980; 210: 1372–1373
   PubMed Web of Science ®Google Scholar
• Rieder R. O., Mann L. S., Weinberger D. K., Van Kammen D. P., Post R. M. Computed tomographic scans in patients with schizophrenia. schizoaffective, and bipolar affective disorder. Archives of General Psychiatry 1983; 41: 602–606
   Google Scholar
• Sandyk R. Pineal calcification and subtypes of tardive dyskinesia. International Journal of Neuroscience 1990; 53: 123–229
   Google Scholar
• Sandyk R. The pineal gland and the mode of onset of schizophrenia. International Journal of Neuroscience, in press
   Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. The protective role of the pineal gland in tardive dyskinesia. International Journal of Neuroscience 1988; 43: 215–218
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroeptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Sandyk R., Kay S. K. Suicidal Behavior and tardive dyskinesia. International Journal of Neuroscience 1991a; 57: 269–271
   PubMed Web of Science ®Google Scholar
• Sandyk K., Kay S. K. The relationship of tardive dyskinesia to positive schizophrenia. International Journal of Neuroscience 1991b; 56: 107–139
   PubMed Web of Science ®Google Scholar
• Sandyk K., Awerbuch G. I., Kay S. K. Pineal calcification and tardive dyskinesia. Lancet 1990; 335: 1528
   PubMed Web of Science ®Google Scholar
• Schooler K. K., Kane J. M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Seibyl J. P., Glazer W. M., Innis R. R. Serotonin function in tardive dyskinesia. Psychiatric Annals 1981; 19: 310–314
   Google Scholar
• Simpson G. M., Lee J. H., Zoubok B., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
   PubMed Web of Science ®Google Scholar
• Spitzer R. L., Endicott J. E., Robins E. Research Diagnostic Criteria (RDC) for a Select group of Functional Disorders. New York State Psychiatric Institute. Bimetrics Research., New York 1978
   Google Scholar
• Trentini G. P., De Gaetani S. F., Criscuolo M., Migaldi M., Ferrari G. Pineal calcification in different physiopathological conditions in humans. Fundamental and clinics in pineal research, G. P. Trentini, C. De Gaetani, P. Pevet. Raven Press., New York 1987; 291–304
   Google Scholar
• Van Praag H. M. Neurotransmitters and CNS disease: Depression. Lancet 1982; 7: 1259–1264
   Google Scholar
• Van Praag H. M. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet 1983; 2: 977–978
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenia and its association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Archives of General Psychiatry 1987; 44: 907–912
   PubMed Web of Science ®Google Scholar
• Waldmeier P. C., Delini-Stula A. A. A. Serotonin-dopamine inter-actions in the nigrostriatal system. European Journal of Pharmacology 1979; 55: 363–373
   PubMed Web of Science ®Google Scholar
• Wechsler D. WAIS-R Manual. Psychological Corporation., New York 1981
   Google Scholar
• Weinberger D. R. Computed tomography (CT) findings in schizophrenia: Speculations on the meaning of it all. Journal of Psychiatric Research 1984; 18: 477–490
   PubMed Web of Science ®Google Scholar
• Welsh M. G. Pineal calcification: structural and functional aspects. Pineal Research Reviews 1985; 3: 41–68
   Google Scholar
• Wyatt R. J., Potkin S. G., Kleinman J. E. The schizophrenia syndrome: examples of biological tools for subclassification. Journal of Nervous and Mental Disease 1981; 169: 100–112
   PubMed Web of Science ®Google Scholar
• Yassa R., Lal S., Korpassy A., Ally J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 1987; 22: 67–72
   PubMedGoogle Scholar
• Yassa R., Nair N. P. V., Iskandar H., Schwartz G. Factors in the development of severe forms of tardive dyskinesia. American Journal of Psychiatry 1990; 147: 1156–1163
   PubMed Web of Science ®Google Scholar
• Yassa R., Nair V., Schwartz G. Early versus late onset psychosis and tardive dyskinesia. Biological Psychiatry 1986; 21: 1291–1297
   PubMedGoogle Scholar
• Yesavage J. A., Bourgeois M., Kraemer H. Prevalence of tardive dyskinesia in 3,140 French inpatients. Journal of Nervous and Mental Disease 1982; 170: 111–112
   PubMedGoogle Scholar
• Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Research 1982; 246: 161–163
   PubMed Web of Science ®Google Scholar